BioNTech SE (BNTX) Net Cash Flow (2018 - 2025)
BioNTech SE (BNTX) posted Net Cash Flow of -$2.8 billion for Q4 2025, down 1450.28% sequentially from -$182.5 million in Q3 2025, and down 2045.25% YoY from $145.4 million in Q4 2024.
BioNTech SE (BNTX) Net Cash Flow (2018 - 2025) Analysis & Trends
BioNTech SE has reported Net Cash Flow for 8 years, with the latest figure at -$2.8 billion in Q4 2025.
- Quarterly Net Cash Flow fell 2045.25% year-over-year to -$2.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.5 billion (down 16.5% YoY) and the FY2025 annual result came in at -$2.3 billion, down 13.77% from the prior year.
- Net Cash Flow slipped to -$2.8 billion in Q4 2025 per BNTX's latest filing, from -$182.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $5.0 billion in Q1 2022 and troughed at -$2.9 billion in Q1 2024.
- A 5-year average of $459.2 million and a median of $243.1 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2025: Net Cash Flow jumped 61737815.84% in 2021, then plunged 2045.25% in 2025.
- Over 5 years, Net Cash Flow stood at $342.5 million in 2021, then surged by 175.69% to $944.2 million in 2022, then tumbled by 311.61% to -$2.0 billion in 2023, then soared by 107.28% to $145.4 million in 2024, then plunged by 2045.25% to -$2.8 billion in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$2.8 billion, -$182.5 million, and $77.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 225.59 Mn |
| 10 | Roivant Sciences | 26.36 Bn | 26.36 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.83 Bn |
| Dec 31, 2025 | -2.83 Bn |
| Sep 30, 2025 | -182.49 Mn |
| Sep 30, 2025 | -182.49 Mn |
| Jun 30, 2025 | 77.88 Mn |
| Jun 30, 2025 | 77.88 Mn |
| Mar 31, 2025 | 475.77 Mn |
| Mar 31, 2025 | 475.77 Mn |
| Dec 31, 2024 | 145.44 Mn |
| Dec 31, 2024 | 145.44 Mn |
| Sep 30, 2024 | -866.39 Mn |
| Sep 30, 2024 | -866.39 Mn |
| Jun 30, 2024 | 1.47 Bn |
| Jun 30, 2024 | 1.47 Bn |
| Mar 31, 2024 | -2.86 Bn |
| Mar 31, 2024 | -2.86 Bn |
| Dec 31, 2023 | -2.00 Bn |
| Dec 31, 2023 | -2.00 Bn |
| Sep 30, 2023 | -796.85 Mn |
| Sep 30, 2023 | -796.85 Mn |